Scarica l'app Stockscreener
63.61
0.84%
-0.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$64.02
Aprire:
$63.99
Volume 24 ore:
371.67K
Relative Volume:
0.08
Capitalizzazione di mercato:
$24.46B
Reddito:
$4.66B
Utile/perdita netta:
$836.30M
Rapporto P/E:
30.39
EPS:
2.093
Flusso di cassa netto:
$1.08B
1 W Prestazione:
+0.43%
1M Prestazione:
-1.18%
6M Prestazione:
-2.63%
1 anno Prestazione:
-4.02%
Intervallo 1D:
$62.93
$64.03
Intervallo di 1 settimana:
$62.58
$66.44
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
63.57 | 24.64B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
99.77 | 174.29B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
342.08 | 129.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.48 | 91.83B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
77.92 | 44.90B | 6.07B | 1.06B | 1.34B | 1.8063 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
Greenup Street Wealth Management Invests in DexCom - National Today
Risk Analysis: Can DexCom Inc be the next market leader2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Trend Recap: Can DexCom Inc be the next market leaderPortfolio Profit Report & High Accuracy Trade Alerts - baoquankhu1.vn
Wells Fargo Maintains DexCom (DXCM) Overweight Recommendation - MSN
DexCom (XSWX:DXCM) Other Assets for Banks - GuruFocus
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom Inc. stock (US2521311074): Is continuous glucose monitoring strong enough to drive U.S. inves - AD HOC NEWS
DexCom Inc (NASDAQ:DXCM) Fits the Affordable Growth Investment Strategy - ChartMill
DXCM (DexCom) Future Policy Benefits - GuruFocus
Alert from law firm on Dexcom withdrawn - marketscreener.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DXCM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Goldman Sachs Adjusts Price Target on DexCom to $82 From $83, Maintains Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Shareholders to Connect - ACCESS Newswire
At US$63.21, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List? - Moomoo
Devon Energy Corp stock: Merger clearance sparks scale questions for investors - AD HOC NEWS
Rathbones Group PLC Sells 18,632 Shares of DexCom, Inc. $DXCM - MarketBeat
Listening to healthcare professionals: Dexcom launches new education offering, Dexcom Academy - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DexCom, Inc. (DXCM) And Encourages Shareholders to Reach Out - ACCESS Newswire
Nisa Investment Advisors Reduces DexCom Stake by Over 50% - National Today
Nisa Investment Advisors LLC Sells 20,529 Shares of DexCom, Inc. $DXCM - MarketBeat
Aberdeen Group plc Acquires 43,990 Shares of DexCom, Inc. $DXCM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Banque Pictet & Cie SA Raises Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom Stock Hits Day Low of $62 Amid Price Pressure - Markets Mojo
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Radcliffe Capital Management, L.P.'s DexCom Inc(DXCM) Holding History - GuruFocus
Devon Energy Corp Stock: Strategic Positioning in North American Oil and Gas Amid Market Volatility - AD HOC NEWS
Is DexCom (DXCM) Fairly Priced After Recent Share Price Weakness? - Yahoo Finance
DexCom Inc (DXCM) Stock Price, Quote, News & History - Benzinga
Mizuho raises DexCom (DXCM) price target to $90 from $78 after earnings beat - MSN
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook By Investing.com - Investing.com Australia
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook - Investing.com India
Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time - Business Wire
SWS Partners Has $3.69 Million Stake in DexCom, Inc. $DXCM - MarketBeat
Compagnie Lombard Odier SCmA Grows Holdings in DexCom, Inc. $DXCM - MarketBeat
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves - Sahm
BNY Mellon Large Cap Securities Fund, Inc.'s DexCom Inc(DXCM) Holding History - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pallas Capital Advisors LLC Decreases Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom, Inc. Experiences Revision in Stock Evaluation Amid Market Pressures - Markets Mojo
DexCom Inc. stock rises Tuesday, still underperforms market - MarketWatch
Soleus Capital Management, L.P.'s DexCom Inc(DXCM) Holding History - GuruFocus
DexCom Inc (DXCM) Stock Price Down 5.81% on Mar 30 - GuruFocus
DexCom, Inc. $DXCM Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Dexcom Inc. Stock: Leader in Continuous Glucose Monitoring Faces Evolving Diabetes Care Landscape - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):